Celesq® Presenters

Email For More Information

Emily  Cook, Esq.

In today’s complex and fast-changing healthcare regulatory environment, Emily Jane Cook helps healthcare organizations thrive. Innovative start-ups and established market leaders alike turn to Emily for broad-spectrum strategies to fuel new business initiatives and solve their most pressing compliance, transactional, reimbursement and litigation challenges. Emily is a practice area leader for the Healthcare Regulatory & Compliance practice. 

In addition to Emily’s role as a national authority on the 340B drug pricing program, Emily helps clients navigate the full suite of federal and state regulations that are essential to healthcare operations. She partners with a wide range of organizations, including non-traditional service providers and new market entrants to identify, protect and expand revenue opportunities, including via private-equity-backed ventures. Her comprehensive counsel encompasses evolving issues such as No Surprises Act (NSA) implementation, development of new provider types, Medicare provider-based and co-location rules, and trends in qui tam litigation and government investigations. She works closely with colleagues in McDermott’s transactional, litigation and private equity practices to deliver fully realized solutions for her clients. 

Emily’s deep insights into US healthcare regulation stem from her previous tenure at the US Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA). For more than five years, she worked with providers and across government agencies to address regulatory barriers to healthcare delivery. She advised senior HHS leadership on Medicare and Medicaid regulation and reimbursement issues affecting rural communities and providers, and served as senior policy advisor to the National Advisory Committee on Rural Health and Human Services.

Programs by Emily  Cook, Esq..

While many 340B stakeholders hoped last year’s federal court decision in the Genesis case regarding the definition of a 340B-eligible “patient” would resolve ongoing uncertainty about when 340B covered entities can use discounted dr...

Program Number
34148
Program Date
2024-08-19
Category
Complex LitigationFederal CourtsFlorida EligibleHealth Care LawPharmaceutical Law
State
CaliforniaColoradoFloridaGeorgiaNew JerseyNew YorkTexas Self Study
Program Credits
Areas of Professional Practice:1 Credit
Total Credits
CLE Credit: 1